Joseph W Polli
Overview
Explore the profile of Joseph W Polli including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
53
Citations
2439
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Elliot E, Polli J, Patel P, Garside L, Grove R, Barnett V, et al.
J Infect Dis
. 2024 Jul;
230(1):e34-e42.
PMID: 39052748
Background: Cabotegravir plus rilpivirine (CAB + RPV) is a guideline-recommended long-acting (LA) injectable regimen for the maintenance of human immunodeficiency virus-1 (HIV-1) virologic suppression. This post hoc analysis summarizes CAB...
2.
Teichner P, Chamay N, Elliot E, Pascual-Bernaldez M, Merrill D, Garris C, et al.
Open Forum Infect Dis
. 2024 Jun;
11(6):ofae282.
PMID: 38882931
Background: Cabotegravir (CAB) + rilpivirine (RPV) dosed monthly or every 2 months is a complete long-acting (LA) regimen for the maintenance of human immunodeficiency virus type 1 virologic suppression. Across...
3.
Oka S, Holohan V, Shirasaka T, Choi J, Kim Y, Chamay N, et al.
HIV Med
. 2023 Dec;
25(3):381-390.
PMID: 38147871
Objectives: Cabotegravir + rilpivirine (CAB + RPV) dosed monthly or every 2 months is the first complete long-acting (LA) regimen recommended by treatment guidelines for the maintenance of HIV-1 virological...
4.
Patel P, Teichner P, Elliot E, Boffito M, Murray M, Polli J, et al.
Ther Adv Infect Dis
. 2023 Dec;
10:20499361231214626.
PMID: 38107552
Cabotegravir (CAB) and rilpivirine (RPV) is the first complete long-acting (LA) injectable regimen recommended by treatment guidelines for the maintenance of HIV-1 virologic suppression in people with HIV-1 who are...
5.
Orkin C, Schapiro J, Perno C, Kuritzkes D, Patel P, DeMoor R, et al.
Clin Infect Dis
. 2023 Jun;
77(10):1423-1431.
PMID: 37340869
Background: Previously reported post hoc multivariable analyses exploring predictors of confirmed virologic failure (CVF) with cabotegravir + rilpivirine long-acting (CAB + RPV LA) were expanded to include data beyond week...
6.
Patel P, Ford S, Baker M, Meyer C, Garside L, DAmico R, et al.
HIV Med
. 2022 Nov;
24(5):568-579.
PMID: 36411596
Background: Limited data exist on pregnant women living with HIV exposed to cabotegravir + rilpivirine (CAB + RPV). Outcomes in pregnant participants exposed to CAB + RPV, and pharmacokinetic washout...
7.
Taskar K, Yang X, Neuhoff S, Patel M, Yoshida K, Paine M, et al.
Clin Pharmacol Ther
. 2022 May;
112(3):573-592.
PMID: 35612761
The role of P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP) in drug-drug interactions (DDIs) and limiting drug absorption as well as restricting the brain penetration of drugs with certain...
8.
Cutrell A, Schapiro J, Perno C, Kuritzkes D, Quercia R, Patel P, et al.
AIDS
. 2021 Mar;
35(9):1333-1342.
PMID: 33730748
Objective: Efficacy and safety of long-acting cabotegravir (CAB) and rilpivirine (RPV) dosed intramuscularly every 4 or 8 weeks has been demonstrated in three Phase 3 trials. Here, factors associated with...
9.
Vormann M, Vriend J, Lanz H, Gijzen L, van den Heuvel A, Hutter S, et al.
J Pharm Sci
. 2021 Feb;
110(4):1601-1614.
PMID: 33545187
Proximal tubule epithelial cells (PTEC) are susceptible to drug-induced kidney injury (DIKI). Cell-based, two-dimensional (2D) in vitro PTEC models are often poor predictors of DIKI, probably due to the lack...
10.
Murad N, Pasikanti K, Madej B, Minnich A, McComas J, Crouch S, et al.
Drug Metab Dispos
. 2020 Nov;
49(2):169-178.
PMID: 33239335
Volume of distribution at steady state (V) is one of the key pharmacokinetic parameters estimated during the drug discovery process. Despite considerable efforts to predict V, accuracy and choice of...